Influence of dietary electrolyte balance, source of added potassium and anticoccidial agents on the performance of male broilers

1. The performance of 1680 male broiler chickens was measured from one to 42 d of age. They were given diets with three (125, 165 and 205 mEq/kg) electrolyte balances (sodium + potassium - chloride), two sources of added potassium (carbonate or sulphate) and two anticoccidial agents (90 mg/kg of either monensin or lasalocid). 2. The dietary treatments had no significant effects on the growth performance of broiler chickens in the starter phase. 3. In the finisher phase, the chickens given the diets containing lasalocid utilised food less efficiently that those given the diets containing monensin. 4. There were significant interactions between dietary electrolyte balance and source of added potassium on body weight gains and food:gain ratios in the finisher phase. In diets with an electrolyte balance of 205 mEq/kg, the inclusion of potassium sulphate instead of potassium carbonate increased body weight gains by 3.4% and reduced food:gain ratios by 4.6%. 5. The body weight gains of chickens given the finisher diets containing lasalocid and added potassium carbonate were reduced by 2.6% compared to those of chickens given the diets containing monensin or added potassium sulphate. 6. The litter moisture content was higher in pens with chickens on the diets with an electrolyte balance of 205 mEq/kg than on the diets with either 125 or 165 mEq/kg. Both lasalocid and potassium sulphate tended to increase the litter moisture content. 7. It may be concluded that the inclusion of 90 mg/kg of either monensin or lasalocid in broiler diets does not alter the balance of electrolytes required for optimum growth performance of broiler chickens.     

Efficacy of oxfendazole as administered by intraruminal injection to naturally infected calves

Oxfendazole, formulated into a 22.5% suspension, was administered by intraruminal injection to cattle at the rates of 0, 1.125, 2.25, 4.50, and 6.75 mg/kg of body weight. In total, 50 naturally infected calves were used, with 10 animals being allocated to each of the 5 treatment groups on the basis of pretreatment counts of nematode eggs per gram of feces. All animals were necropsied 7 days after treatment. The trial was done between December 1983 and January 1984, with the animals kept on concrete for a minimum of 35 days immediately before necropsy. For all nematodes and stages combined, efficacies were 97.4%, 98.8%, 99.5%, and 99.8% for oxfendazole at dosages of 1.125, 2.25, 4.50, and 6.75 mg/kg of body weight, respectively. Early 4th-stage larvae of Ostertagia and Nematodirus helvetianus adults were eliminated at rates greater than 93% only at the dosages of 4.50 mg/kg and above. Local or systemic adverse reactions were not observed in any of the animals.     

Influence of lasalocid level on forage intake, digestibility, ruminal fermentation, liquid flow and performance of beef cattle grazing winter range

Three experiments were conducted to study the effects of lasalocid level on performance, intake, digestibility, ruminal fermentation and fluid flow of beef cattle grazing dormant, tallgrass prairie. In Exp. 1, 120 pregnant, mature beef cows of primarily Hereford breeding (avg wt = 471 kg) were randomly assigned to received 0, 100, 200 or 300 mg lasalocid X head-1 X d-1 in 1.82 kg supplement. Weight changes at 30, 60 or 90 d, condition score change and calf birth weight were not affected (P greater than .10) by lasalocid level. In Exp. 2, estimates of intake and digestibility were obtained with 40 pregnant, mature Hereford cows (avg wt = 474 kg) and 12 esophageal-cannulated, Hereford X Angus steers (avg wt = 225 kg), using Yb and indigestible acid detergent fiber as markers for fecal output and digestibility, respectively. Levels of lasalocid provided to cows and steers were similar, on a body weight (BW) basis, to those in Exp. 1 and corresponded to approximately 0, .22, .44 or .66 mg lasalocid/kg BW. Total diet and forage organic matter digestibility for beef cows decreased (P less than .01) at the .22 mg/kg BW level, but increased at the .44 and .66 mg/kg BW levels. Organic matter intake was not influenced (P greater than .10) by lasalocid addition. In Exp. 3, 16 ruminal-cannulated, Hereford X Angus steers (avg wt = 227 kg) were given the same lasalocid dosages per kg BW as in Exp. 2, and were used to study the effects of lasalocid on ruminal fermentation and fluid flow characteristics.(ABSTRACT TRUNCATED AT 250 WORDS)     

Effects of lasalocid on coccidial infection and growth in young dairy calves.

Effects of lasalocid on coccidial infection and on calf growth were examined in 16 Holstein bull calves. Calves were assigned randomly to a 2 x 2 factorial arrangement of starter ration containing 0 or 40 mg of lasalocid/kg of starter, beginning when calves were 3 days old (SE = 0.046), and single oral inoculation with 0 or 30,000 sporulated oocysts (Eimeria bovis) at 28 days. Pelleted calf starter was fed ad libitum from day 1; milk replacer was fed at a rate of 3.6 kg/d until day 28. Mean daily gain, dry-matter intake, and body weight were increased in calves fed lasalocid and decreased in those inoculated with coccidia. Addition of lasalocid to the feed improved gains by 8% in uninoculated calves and by 50% in inoculated calves. Fecal oocyst numbers were reduced when lasalocid was fed to inoculated calves. Feces were more abnormal in calves inoculated with coccidia. Respiration rates, rectal temperatures, PCV, and serum sodium and potassium concentrations were unaffected by treatment. On the basis of findings in this study, lasalocid minimized effects of coccidial challenge inoculation and increased growth of calves.     

Control of coccidia in young calves using lasalocid

SUMMARY Thirty-six, 2- to 4-day-old Friesian bull calves were divided into 4 groups and fed milk replacer and calf starter pellets ad libitum in separate pens. Four treatments were applied; lasalocid in milk (1 mg/kg body weight/day) (M), lasalocid in starter (F), lasalocid in both milk and starter (M+F) and untreated (C). When the calves were about 2 weeks old they were each dosed orally with 550 000 sporulated Eimeria sp oocysts, mainly E zurneii and E bovis. The infection, detected by faecal excretion of oocysts, was suppressed in the M+F and M groups. There was significant excretion of oocysts in the F group but these calves did not show any clinical signs of coccidiosis. Untreated calves were affected with diarrhoea containing blood on the 24th day after inoculation. Body weight gain and intake of starter pellets was also depressed in the untreated calves during the time they were clinically affected. It is concluded that mixing lasalocid in milk replacer (or fresh milk) is an effective method of protecting young calves against early infection with coccidia.     

Performance and ruminal changes of early-weaned calves fed lasalocid

Twenty-two neonatal calves were assigned to a control or lasalocid-fed group and weaned at 3 wk of age. They were fed a prestarter diet from 3 d of age until they consumed 227 g/d and then a mixture of 227 g prestarter daily and starter diet in ad libitum amounts. The lasalocid-fed group received lasalocid in milk at 1 mg/kg body weight daily from 4 to 7 d and at .5 mg/kg body weight daily in milk and medicated prestarter diet (88 mg lasalocid/kg) during the 2nd wk. After 2 wk, lasalocid-fed calves were given medicated prestarter and starter (44 mg lasalocid/kg) diets. Four calves in each group were ruminally cannulated at 3 to 5 d of age, and ruminal contents were obtained at weekly intervals to monitor microbial activity. Rectal fecal samples were collected from all calves and examined for coccidial oocysts. Lasalocid-fed calves had a greater weekly feed intake and weight gain than control calves after 6 wk of age. Total ruminal volatile fatty acid concentrations were higher, but the acetate:propionate ratio was lower in lasalocid-fed calves than in control calves. Total viable anaerobic and amylolytic bacterial counts were higher in lasalocid-fed calves than in control calves. No significant treatment effect was found for ruminal NH3-N concentration or ruminal lasalocid-resistant, lactobacilli, lactate-utilizing, cellulolytic or methanogenic bacterial numbers. No evidence of coccidiosis was detected in either group. In general, lasalocid-fed calves had greater feed intake, weight gain and ruminal microbial activity than the calves fed no lasalocid in the diet.     

Reduction of 3-methylindole production and prevention of acute bovine pulmonary edema and emphysema with lasalocid

A study was conducted to determine the dose of lasalocid that would effectively reduce ruminal conversion of tryptophan (TRP) to 3-methylindole (3MI) and prevent the development of acute bovine pulmonary edema and emphysema (ABPE). After adaptation to a maintenance diet for 3 wk, 20 mature beef cows were randomly divided into four groups of five cows each and fed 0, 200, 400 or 600 mg lasalocid X head-1 X d-1 in .5 kg ground barley for the 12-d experimental period. In vitro conversion of TRP to 3MI and indole by ruminal fluid and volatile fatty acid (VFA) concentrations were determined on d 0, 2, 4, 6 and 12. On d 6, an oral dose of .35 g TRP/kg body weight was given to induce ABPE, and ruminal production of 3MI and indole was determined at intervals thereafter. Formation of 3MI was sharply reduced (P less than .01) both in vitro and in vivo by lasalocid treatment at 200 mg X head-1 X d-1. Further suppression of 3MI production occurred as the lasalocid dose was increased (P less than .05). Linear (P less than .0001) and quadratic (P less than .002) components were determined for the relationship between lasalocid dose and 3MI production. Indole formation was variable, but tended to increase (P less than .05) with increasing lasalocid dose. Cows that received no lasalocid developed moderate to severe clinical signs of ABPE and three cows died of acute lung disease. Lasalocid treatment at all levels prevented ABPE. Lasalocid decreased ruminal acetate and butyrate, and increased propionate concentration (P less than .01).(ABSTRACT TRUNCATED AT 250 WORDS)     

Lasalocid toxicity in cattle: acute clinicopathological changes

Thirty-six steers (148 to 500 kg) divided into six equal groups were used in a toxic syndrome study of lasalocid and monensin given as a single oral dose. One group was given a placebo, a second group received monensin (25 mg/kg body weight) and the other four groups received lasalocid at 1, 10, 50 or 100 mg/kg body weight (bw). No toxic signs developed in cattle given placebo or lasalocid at 1 or 10 mg/kg bw dose. The earliest toxic signs were muscle tremors, tachycardia and rumen atony. After 24 h, the cattle were dehydrated, anorectic and had diarrhea. Deaths occurred between d 1 and 22.5 in the groups receiving lasalocid at 50 and 100 mg/kg bw and monensin. Altered values in blood leucocytes, erythrocytes, hemoglobin, hematocrit, total protein, albumin, creatinine, urea nitrogen, total bilirubin, creatine kinase, lactic dehydrogenase, calcium, chloride and inorganic phosphate occurred 1 d after dosing: urine pH and specific gravity also changed 1 d after dosing. Maximum changes occurred at d 3. Most of the changes were indicative of dehydration rather than specific organ damage.     

Short-term effect of antibiotic feeding on site and extent of digestion of growing and finishing diets in feedlot cattle

Two metabolism trials were conducted to evaluate the influence of therapeutic antibiotic supplementation on characteristics of digestion of growing and finishing diets. Treatments consisted of a basal diet supplemented with: no antibiotics, 350 mg chlortetracycline and 350 mg sulfamethazine and 700 mg chlortetracycline and 700 mg sulfamethazine. In trial 1, treatment effects were evaluated in a replicated 3 X 3 Latin-square design experiment involving six crossbred steers (462 kg) with cannulas in the rumen and proximal duodenum. The basal diet contained (dry matter basis) 16.1% alfalfa hay, 72% steam flaked corn, 3.3% molasses, 5.8% fat, .96% urea, .79% limestone, .50% trace mineral salt, 33 mg/kg lasalocid, 2,200 IU/kg vitamin A and .44% chromic oxide. Dry matter intake was limited to 1.4% of body weight. In trial 2, treatment effects were evaluated in a 3 X 3 Latin-square design experiment involving three steers (399 kg) with cannulas in the rumen and proximal duodenum. The basal diet contained (dry matter basis) 10.1% sudangrass hay, 34.9% alfalfa hay, 43.9% steam flaked corn, 6.1% molasses, 4.0% fat, .46% urea, .49% trace mineral salt, 33 mg/kg lasalocid and 2,200 IU/kg vitamin A. Dry matter intake was limited to 1.65% of body weight. Antibiotic supplementation did not influence microbial efficiency, passage of microbial and feed N to the small intestine, or either ruminal or total tract digestion of organic matter and acid detergent fiber in either growing or finishing diets (P greater than .20).(ABSTRACT TRUNCATED AT 250 WORDS)     

Evaluation of lasalocid as a coccidiostat in calves: titration, efficacy, and comparison with monensin and decoquinate

Two experiments were conducted to evaluate lasalocid as a coccidiostat in Holstein calves and to compare lasalocid with monensin and decoquinate. In experiment 1, calves in 3 groups (6 calves/group) were each inoculated with 500,000 sporulated oocysts, 88% of which were Eimeria bovis and 12% were E zuernii. Calves in each group were given lasalocid-medicated feed at 0.50 (group 3), 0.75 (group 4), or 1 mg/kg (group 5) of body weight/day for 45 days. Two control groups (6 calves/group) were also evaluated; calves in control group 2 were inoculated and nontreated, and calves in control group 1 were noninoculated and nontreated. At 0.50, 0.75, or 1 mg/kg/day, lasalocid was equally effective in preventing induced coccidiosis (E bovis and E zuernii) in calves. Compared with inoculated nontreated controls, treated calves had significantly (P less than 0.05) fewer oocysts in feces and had fewer clinical signs of coccidiosis from days 16 to 30 after inoculation. Experiment 2 was conducted to compare the effectiveness of monensin, lasalocid, and decoquinate for the prevention of experimentally induced coccidiosis. Calves (n = 48) were allotted into 4 groups (12 calves/group); each was inoculated orally with 275,000 sporulated oocysts, predominantly E bovis and E zuernii, and each was given nonmedicated feed (group 6) or feed medicated with 33 mg of lasalocid (group 7), decoquinate (group 8), or monensin (group 9)/kg of feed for 46 days. Calves given medicated rations had significantly (P less than 0.05) fewer oocysts in their feces and fewer clinical signs of coccidiosis than did calves given nonmedicated rations.(ABSTRACT TRUNCATED AT 250 WORDS)     

Pathologic changes associated with experimental lasalocid and monensin toxicosis in cattle

The acute toxicity of lasalocid and monensin was studied in 36 Holstein steers. The cattle were given (orally) a single dosage of lasalocid (1, 10, 50, or 100 mg/kg of body weight) or monensin (25 mg/kg of body weight) or rice hulls. Animals were observed once a day until they died or were euthanatized at 32 days after the dose was given. All cattle were necropsied. Heart, kidney, adrenal gland, liver, spleen, pancreas, lungs, brain, sciatic nerve, skeletal muscle, small intestine, large intestine, and rumen tissue sections, stained with hematoxylin and eosin, were studied microscopically. Lasalocid was lethal at dosages of 50 and 100 mg/kg, and monensin was lethal at the dosage given (25 mg/kg). Cattle dying of lasalocid and monensin toxicoses had gross and microscopic lesions consistent with cardiomyopathy. Dilated heart or petechial and ecchymotic hemorrhages were observed with both drugs. Microscopically, multifocal areas of myocyte necrosis were observed. Those cattle that died within 3 days of dosing with either drug had a marked degranulation of pancreatic acinar cells. Changes were not observed in any other tissues.     

Effect of dietary supplementation with oregano essential oil on performance of broilers after experimental infection with Eimeria tenella.

A study was carried out to examine the effect of dietary supplementation of oregano essential oil on performance of broiler chickens experimentally infected with Eimeria tenella at 14 days of age. A total of 120 day-old Cobb-500 chicks separated into 4 equal groups with three replicates each, were used in this study. Two groups, one infected with 5 x 10(4) sporulated oocysts of E. tenella and the other not, were given a basal diet and served as controls. The other two groups also infected with E. tenella were administered diets supplemented with oregano essential oil at a level of 300 mg/kg, or with the anticoccidial lasalocid at 75 mg/kg. Following this infection, survival rate, bloody diarrhoea and oocysts excretion as well as lesion score were determined. Throughout the experimental period of 42 days, body weight gain and feed intake were recorded weekly, and feed conversion ratios were calculated. Two weeks after the infection with E. tenella supplementation with dietary oregano oil resulted in body weight gains and feed conversion ratios not differing from the non-infected group, but higher than those of the infected control group and lower than those of the lasalocid group. These parameters correspond with the extent of bloody diarrhoea, survival rate, lesion score and oocyst numbers and indicated that oregano essential oil exerted an anticoccidial effect against E. tenella, which was, however, lower than that exhibited by lasalocid.     

Pharmacokinetics, metabolism and urinary detection time of flunixin after intravenous administration in camels

The pharmacokinetics of flunixin were determined after an intravenous dose of 1.1 mg/kg body weight in six camels and 2.2 mg/kg body weight in four camels. The data obtained (mean ±  SEM) for the low and high dose, respectively, were as follows:
  The elimination half-lives ( t _½β) were 3.76 ± 0.24 and 4.08 ± 0.49 h, the steady state volumes of distribution ( V d_ss) were 320.61 ± 38.53 and 348.84 ± 35.36 mL/kg body weight, total body clearances ( Cl _T) were 88.96 ± 6.63 and 84.86 ± 4.95 mL/h/kg body weight and renal clearances ( Cl _r) were 0.52 ± 0.09 and 0.62 ± 0.18 mL/h/kg body weight. A hydroxylated metabolite of flunixin was identified by gas chromatography/mass spectrometry (GC/MS) under electron and chemical ionization and its major fragmentation pattern was verified by tandem mass spectrometry (GC/MS/MS) using neutral loss, daughter and parent scan modes. The detection times for flunixin and its hydroxylated metabolite in urine after an intravenous (i.v.) dose of 2.2 mg/kg body weight were 96 and 48 h, respectively.     

The safety of dirlotapide in dogs

The safety of dirlotapide in dogs was evaluated in two studies with parallel designs. In an acute tolerance study, 24 beagles (six dogs per treatment) were treated orally once daily for 14 days with placebo or dirlotapide at 2.5, 5.0, or 10.0 mg/kg/day. In a margin-of-safety study, 38 overweight, neutered beagles were treated orally once daily for 3 months with dirlotapide at doses up to 0.5 mg/kg/day (six dogs), 1.5 mg/kg/day (12 dogs) and 2.5 mg/kg/day (six dogs). Control dogs received placebo at 0.3 mL/kg/day (10 dogs) and 0.5 mL/kg/day (four dogs). Results were similar for both studies, and no serious adverse events were observed. Dirlotapide was clinically well-tolerated in dogs at dosages up to 10 mg/kg/day for 14 days and 2.5 mg/kg/day for 3 months. Dirlotapide produced the expected decrease in food intake and body weight (up to 20–40%) without ill effects. Clinical, pathologic, and histopathologic findings were reversible and consistent with suppression of food intake and rapid weight loss produced by elevated dirlotapide dosages. In both studies, sporadic emesis and loose stools were observed in both placebo and dirlotapide-treated dogs. Incidence of emesis generally increased with dose and decreased with treatment time. Elevations in hepatic transaminase activity were seen in dogs treated with more than 1.5 mg/kg dirlotapide daily, but were not associated with clinical signs or microscopic evidence of hepatic degeneration or necrosis.     

Dose titration of oxfendazole against common nematodes of swine.

Oxfendazole, a benzimidazole carbamate, was administered as a 0.5% feed additive to 88 pigs naturally infected with two to four nematode species. Dose rates of 1.5 mg/kg of body weight, 3.0 mg/kg, 3.75 mg/kg, 4.5 mg/kg, 6.75 mg/kg, or 9.0 mg/kg were 100% efficacious against Oesophagostomum dentatum and 99.2% to 100% effective against Ascaris suum. Dose rates of 4.5 mg/kg, 6.75 mg/kg, and 9.0 mg/kg were 92.7%, 98.9%, and 99.5% effective, respectively, against mixed populations of Metastrongylus apri and M pudendotectus. Results were variable with Trichuris suis infections. Efficacy was based on the number of nematodes recovered at necropsy. Palatability and acceptability of the feed additive were good, and adverse reactions following administration were not observed.     

Efficacy and safety of dirlotapide in the management of obese dogs evaluated in two placebo-controlled, masked clinical studies in North America

Dirlotapide was evaluated in the management of obesity in dogs in two multicenter, clinical studies in North America. A total of 335 obese dogs of various breeds were randomized to dirlotapide or placebo in a 2:1 ratio. Dirlotapide was administered orally once daily to dogs at an initial dose of 0.05 mg/kg, increased after 14 days to 0.1 (study B, label dose) or 0.2 mg/kg (study A) and then adjusted according to individual weight loss at 28-day intervals. Dogs were examined and weighed, and body condition scores (BCSs) were recorded every 28 days. Study A had three consecutive phases: weight loss (16 weeks, day 0–112); weight management (12 weeks); and post-treatment (8 weeks). Study B had a weight loss phase only. For dirlotapide-treated dogs, mean weight loss by day 112 was 11.8–14.0% compared with 3.0–3.9% for placebo ( P  = 0.0001). In study A, weight losses for dirlotapide were 19.3% after 12 weeks of weight management and 16.7% (regain of 3.4%) by 8 weeks after dirlotapide was discontinued. In both studies, dogs in both treatments had emesis, lethargy, anorexia, diarrhea, and mildly elevated hepatic transaminase activity, that resolved spontaneously with time. These were experienced more frequently with dirlotapide. Improved activity levels and BCS for >50% dogs were reported with dirlotapide. Dirlotapide was safe and effective in the reduction and management of body weight in obese dogs.     

Effect of lasalocid on weight gains, ruminal fermentation and forage intake of stocker cattle grazing winter wheat pasture

Fifty fall-weaned heifers with initial weights of 209 kg (yr 1) and 222 kg (yr 2) were used to determine effects of lasalocid on weight gains, forage intake and ruminal fermentation of stocker cattle grazing winter wheat pasture. The heifers grazed a single wheat pasture for about 100 d each year, and were individually fed 1.06 kg of supplement (6 d/wk) pro-rated to supply 0, 100 or 200 mg lasalocid.head-1.d-1. Also, eight mature Hereford steers with large rumen cannula were used to evaluate further effects of lasalocid (0 or 300 mg) on ruminal fermentation during two grazing periods (immature and mature wheat forage) of yr 2 and an additional third year. Daily gains of heifers fed 200 mg lasalocid/d were .11 kg greater (P less than .05) than those of heifers fed 0 or 100 mg lasalocid/d. One hundred milligrams lasalocid did not increase weight gains. Digestibilities of forage dry matter (DM) and organic matter (OM) were similar (P greater than .05) among treatments, and lasalocid did not affect (P greater than .10) forage intake. Ruminal ammonia concentrations (10.57, 15.22 and 17.81 mg/dl +/- 1.71) were increased (P less than .05) by both levels of lasalocid in yr 1, but differences among treatment means of 8.32, 11.95 and 11.66 (SE +/- 1.44) were not significant in yr 2. Lasalocid did not consistently affect total volatile fatty acids concentrations. The acetic:propionic acid ratios in heifers were not different (P greater than .05) among treatments, but were decreased (P less than .10) by lasalocid in cannulated steers.(ABSTRACT TRUNCATED AT 250 WORDS)     

Biologic activity of dirlotapide, a novel microsomal triglyceride transfer protein inhibitor, for weight loss in obese dogs

Dirlotapide is a novel microsomal triglyceride transfer protein inhibitor intended for the treatment and management of obesity in dogs. The biologic effects of dirlotapide, weight loss, decreased food intake, increased fecal fat, decreased serum cholesterol, and body composition, were evaluated in a controlled, blinded study. Sixteen obese beagles were randomized to treatment with placebo ( n  = 4) or dirlotapide ( n  = 12) following a 2-week acclimation period in which baseline data were collected. The dirlotapide dose, adjusted to produce weight loss for 3 months and then stabilize body weight for 1 month (weight management), produced a significant difference (expressed as a percentage of baselines) in weekly weight loss, food intake, fecal fat, serum cholesterol concentration, and body composition (measured by dual energy X-ray absorptiometry) compared with placebo treatment ( P  < 0.05). The initial dirlotapide dosage of 0.5 mg/kg (10 times the initial label dose) resulted in a high rate of weight loss (3.3% weekly) and anorexia, emesis, and loose stools for some dogs. A 25% dose reduction (mean dosage: 0.36 mg/kg) followed by biweekly 25% dose adjustments based on individual weight loss, produced 1–2% weekly weight loss and total weight loss of 18.8% in 12 weeks at a final mean dosage of 0.41 mg/kg (range: 0.15–0.60); a dosage range of 0.10–0.34 mg/kg stabilized body weight. Body weight changes for placebo-treated dogs were −0.8% to +0.9% weekly; total weight gain during the weight loss phase was 10.6%. No apparent change in food intake, percentage of fecal fat, and serum cholesterol was observed in the placebo group. Food intake and body weight increased when dirlotapide was discontinued. Dirlotapide produced weight loss by both reducing appetite (about 90% of the weight loss activity) and by increasing fecal fat excretion (about 10% of the weight loss activity).     

An evaluation of dirlotapide to reduce body weight of client-owned dogs in two placebo-controlled clinical studies in Europe

The clinical efficacy for weight loss and safety of dirlotapide in dogs were evaluated in two multi-centre studies with parallel designs. Overweight, adult dogs ( n  = 245) of various breeds were randomized to treatment with dirlotapide or placebo in a 2:1 ratio. Dirlotapide was administered orally once daily to dogs at an initial dose of 0.05 mg/kg/day commencing on day 0 and doubled after 14 days. Every 28 days, dogs were examined, weighed, body condition scores (BCS) were recorded, and dose was adjusted to meet weight loss targets. Each study comprised three consecutive phases: weight-loss (up to day 196); weight-stabilization (84 days); and post-treatment (28 days). pre-treatment feeding and exercise regimens were continued during treatment. Dirlotapide-treated dogs showed mean weight loss of 15.9% (study A) and 14.0% (study B) by the end of weight loss phase (up to day 196). Percentage weekly weight losses for dirlotapide were significantly greater than for placebo ( P  ≤ 0.0002). Emesis and diarrhoea were experienced in both treatments but were more frequent with dirlotapide; resolution was spontaneous. BCS improved for 75.7–82.5% of dogs on dirlotapide treatment compared with 15.4–41.4% for placebo. Mean dirlotapide dosage at end of weight-loss phase was 0.38 (study A) and 0.29 (study B) mg/kg initial body weight/day. Dirlotapide was found to be clinically safe and effective in the reduction of body weight in overweight dogs.     

The effect of lasalocid on apparent digestibility, characteristics of rumen fermentation and fattening and slaughter output of bulls

Four digestion experiments with 5 wethers each (Feeding: artificially dried grass; 0, 15, 30 or 60 mg lasalocid per animal and day), two short time experiments (Exp. 1: 3 rumen fistulated sheep; feeding; artificially dried grass; 0, 15, 30 or 60 mg lasalocid per animal and day; exp. 2: 20 bulls; feeding; 2 kg concentrates per animal and day; wheat straw ad libitum; 0, 150 or 300 mg lasalocid per animal and day) and one individual feeding experiment (24 bulls per group; duration: 279 days, feeding: 2 kg concentrates per animal and day, corn silage and whole barley-grass silage ad libitum; 0 or 100/200 mg lasalocid per animal and day) were carried out in order to investigate the influence of the ionophore lasalocid on digestibility, figures of rumen fermentation as well as fattening and slaughtering results of bulls. Higher doses of lasalocid (30 and 60 mg per animal and day) decreased significantly digestibility of organic matter (1.8 and 2.8 units) and crude fibre (5.8 and 7.2 units). Relative acetate (22 to 120 mmoles per mol) and butyrate concentration (23 to 58 mmoles per mol) were decreased and molar propionate concentration of rumen liquid (25 to 154 mmoles per mol) was increased depending on level of lasalocid supplementation. Lasalocid did not significantly influence the dry matter intake; daily weight gain and slaughtering results were increased (4.4 and 6.1%), energy efficiency was improved (3.8%). Effects of lasalocid are similar to that of monensin. A dose of 20 to 30 mg lasalocid per kg dry matter is recommended.